CELL & GENE COLLABORATIVE BLOG

ARW’s CGT+RNA Manufacturing Must-Reads (BAD PICKUP LINES EDITION!)
Day-in and day-out, I write, read, listen to, and watch as much content as I can about CGT and RNA therapy manufacturing, in particular, and/or other ATMP industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email.
Continue Reading..

From Capacity To Comparability: The Shifting Onus In Cell & Gene Therapy Outsourcing
As we continue progressing beyond the COVID (i.e., the seller’s) economy, both Haskett and Graskemper agree we’re steadily seeing biotechs taking on a much more empowered role in negotiating with and securing CDMO partners. But they also see several shifts in the CGT development landscape that could impact both biotechs and their outsourcing partners equally — for the better, or if we’re not careful, for the worse.
Continue Reading..

ARW’s CGT+RNA Manufacturing Must-Reads (GOOGLE SEARCH EDITION!)
Day-in and day-out, I write, read, listen to, and watch as much content as I can about CGT and RNA therapy manufacturing, in particular, and/or other ATMP industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email.
Continue Reading..

Sarepta’s FDA Adcom: Manufacturing Comparability In The Real World
There are a few must-know details about the why & how of Sarepta’s comparability exercise, which I’ll outline for you here. But it wasn’t the facts and figures underpinning the comparability assessment itself that I found the most noteworthy; rather, this adcom served as an important reminder about the overall role comparability can and likely will play in the regulation of our advanced therapies moving forward.
Continue Reading..

ARW’s CGT+RNA Manufacturing Must-Reads (COMPLAINTS EDITION!)
Day-in and day-out, I write, read, listen to, and watch as much content as I can about CGT and RNA therapy manufacturing, in particular, and/or other ATMP industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email.
Continue Reading..

FDA To Sarepta’s Gene Therapy: “Express Yourself…Maybe?”
Though we cling to — and simultaneously despair over — the fact that regulatory experiences are product-specific, the hurdles/debates Sarepta faced remind us of the scientific and clinical complexities our future CGT products will no doubt be faced with during their own BLA reviews.
Continue Reading..

ARW’s CGT+RNA Manufacturing Must-Reads (Weird Contest Edition!)
Day-in and day-out, I write, read, listen to, and watch as much content as I can about CGT and RNA therapy manufacturing, in particular, and/or other ATMP industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email.
Continue Reading..
![“Alice In [The mRNA] Wonderland:” 3 Realities Facing The mRNA Industry GettyImages-940980974](https://vertassets.blob.core.windows.net/image/7cdb640f/7cdb640f-d1dd-413d-8383-4e7d497b367e/300_200-gettyimages_940980974.jpg)
“Alice In [The mRNA] Wonderland:” 3 Realities Facing The mRNA Industry
The mRNA industry is an exciting place to be, and I have no doubt we will celebrate some significant triumphs in the future. But there are three critical realities (or perhaps difficult truths) I was reminded of during the mRNA Therapeutics Summit worth reiterating to keep us grounded through all our uninhibited dreaming.
Continue Reading..

ARW’s CGT+RNA Manufacturing Must-Reads (OUTLANDISH ‘HOLIDAY’ EDITION!)
Day-in and day-out, I write, read, listen to, and watch as much content as I can about CGT and RNA therapy manufacturing, in particular, and/or other ATMP industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email.
Continue Reading..

A Meditation On Change In The CGT Manufacturing Space
A few weeks ago, I published an article recapping my biggest takeaways from the PDA ATMP conference. Throughout the many technical discussions of the two-day event, I was predominantly struck by how often the conversation circled back to the importance of humility and self-improvement in our CMC. Since publishing that article, I’ve continued to read and hear more about the importance of “growing up” in CMC.
Continue Reading..
ARCHIVED ARTICLES
- A “Portrait” of Risk In Cell & Gene Manufacturing
- ARW’s CGT+RNA Manufacturing Must-Reads (Sports Cliché Edition!)
- From The Lion King To Cell & Gene: “The Circle of Life” For Sustainable CGT Products & Businesses
- “Our CMC, Ourselves:” 3 Iterative [Self] Improvements In Cell & Gene Manufacturing
- ARW'S CGT + RNA Manufacturing Must-Reads (SPAM EMAIL EDITION!)
- The “Corps de Manufacturing:” Defining Flexibility In Cell & Gene Therapy Tech Platforms
- Defining Risk-Sharing In Cell & Gene Therapy Manufacturing Partnerships
- ARW's CGT+RNA Manufacturing Must-Reads (Oscar The Grouch Edition!)
- Where Fly-Fishing Meets mRNA: The Art Of mRNA Immunogenicity
- ARW’s CGT+RNA Manufacturing Must-Reads (Greeting Card Edition!)
This website uses cookies to ensure you get the best experience on our website. Learn more